E. Im
Henry Ford Health · 21 works · 435 citations · h-index 7
Top works
- Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
- 1399P Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
- LBA3_PR KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1–positive NSCLC after platinum-based therapy
- Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
- Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer
- LBA36 Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET
- Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer
- Safety, pharmacodynamic, and pharmacokinetic profile of TSR-042, an anti–PD–1 monoclonal antibody, in patients (pts) with advanced solid tumors
- 272 Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study
- Safety and efficacy of the anti–PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer
- Olfactory Neuroblastoma With Divergent Differentiation: Contemporary Management of Unusual Pathology and Literature Review
- 83 Time course of adverse events during dostarlimab treatment in patients with recurrent or advanced endometrial cancer in the garnet trial
- 76P Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial
- Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer
- 991P Treatment-related adverse events (TRAEs) occurring during dostarlimab therapy in the GARNET study
- Is there an increased risk of otitis media in children with obstructive sleep apnea?
- Subtotal Middle Turbinate Resection in Patients with Chronic Rhinosinusitis with Nasal Polyps is Unlikely to Cause Empty Nose Syndrome: A Multi‐Institutional Prospective Study
- 858P Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab
- SO-9 Analysis of the immune-related endpoints of the mismatch repair–deficient non-endometrial solid cancers cohort from the GARNET study
- Abstract OT2-6-13: A randomized phase 2 study of the triplet combination of ridaforolimus (RIDA), dalotuzumab (DALO) and exemestane (EX) compared to the ridaforolimus, exemestane doublet in high proliferation, estrogen receptor positive (ER+) advanced breast cancer